Ampa Health

Ampa Health is a biotechnology company focused on developing next-generation treatments for central nervous system (CNS) disorders, with a primary emphasis on mental health. The company was co-founded by Dr. Husseini Manji, the former Global Head of Neuroscience at Johnson & Johnson, who was instrumental in the development of the antidepressant Spravato. Ampa Health leverages a precision medicine approach to target the glutamatergic system, specifically through the modulation of AMPA receptors. Their goal is to create rapid-acting and more effective therapies for conditions such as major depressive disorder and treatment-resistant depression. Backed by prominent investors like ARCH Venture Partners and Mubadala Capital, the company is currently advancing its pipeline through the pre-clinical stage. Ampa Health represents a significant effort to translate deep neurobiological insights into transformative psychiatric medicines.